CEO Jayson Rieger Buys $125,750 of Verrica Stock in Open Market
VRCA sits 43% above its 52-week low of $3.28.
Summary
Verrica Pharmaceuticals CEO Jayson Rieger bought $125,750 of company stock in open-market purchases on August 14 and 17, 2026.
Key Events · Ownership and Investor Activity · VRCA
-
CEO Open-Market Purchase
CEO and President Jayson Rieger acquired 25,000 shares for $125,750 in two open-market transactions on August 14 and 17, 2026, at prices ranging from $4.91 to $5.06 per share.
-
Financial Impact
The purchase represents approximately 0.156% of the company's market capitalization and increases Rieger's direct holdings to 207,593 shares.
-
Context: Going Concern Warning
The purchase follows the August 6, 2026 10-Q that included a going concern warning and a new $27.5M credit facility from the Chairman, making the CEO's personal investment a notable signal of confidence.
-
Timeline
Transactions occurred on August 14 and 17, 2026, with the Form 4 filed on August 18, 2026.
Analysis · VRCA · Life Sciences
CEO and President Jayson Rieger purchased 25,000 shares for $125,750 at prices between $4.91 and $5.06. This is a real-money open-market buy, not an option exercise or grant. The purchase comes just days after the company's Q2 2026 10-Q disclosed a going concern warning and a new $27.5M credit facility from its Chairman. Rieger's buy is a modest but meaningful vote of confidence from the top executive at a time when the company's cash runway is under scrutiny.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VRCA was trading at $4.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.4M. The 52-week trading range was $3.28 to $9.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.